author
contribut
equal
work
experiment
anim
data
show
protect
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
human
monoclon
antibodi
mab
feasibl
effect
immun
prophylaxi
human
broad
coverag
differ
strain
sarscov
control
potenti
neutral
escap
variant
requir
combin
virusneutr
noncompet
mab
may
properti
human
mab
shown
complet
prevent
lung
patholog
abolish
pharyng
shed
sarscov
infect
ferret
gener
vitro
sarscov
variant
escap
neutral
singl
mutat
glycoprotein
spike
escap
viru
vitro
experi
confirm
bind
recombin
fragment
amino
acid
residu
harbor
mutat
abolish
therefor
screen
antibodyphag
librari
deriv
blood
convalesc
sar
patient
antibodi
complementari
novel
mab
identifi
neutral
escap
virus
compet
bind
recombin
fragment
bound
fragment
deriv
civet
cat
sarscovlik
strain
escap
variant
could
gener
mixtur
mab
show
neutral
sarscov
synergist
fashion
recogn
differ
epitop
receptorbind
domain
dose
reduct
indic
observ
respect
neutral
enhanc
sarscov
infect
subneutr
antibodi
concentr
concern
show
antisarscov
antibodi
convert
abort
infect
primari
human
macrophag
sarscov
product
one
combin
two
noncompet
human
mab
potenti
control
immun
escap
extend
breadth
protect
time
synergi
may
allow
lower
total
antibodi
dose
administ
passiv
immun
prophylaxi
sarscov
infect
sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
spread
guangdong
provinc
southern
china
countri
asia
europ
north
america
result
case
death
main
epidem
stop
late
intern
coordin
public
health
measur
includ
earli
isol
sar
patient
quarantin
contact
consider
econom
cost
affect
countri
number
isol
sar
case
occur
china
asian
countri
case
link
laboratori
unknown
exposur
other
commun
acquir
associ
exposur
live
game
anim
restaur
trade
guangdong
provinc
sarscovlik
virus
almost
ident
patient
isol
found
palm
civet
cat
investig
period
phylogenet
analysi
approxim
sarscov
isol
human
civet
cat
collect
reveal
sar
zoonot
diseas
evolv
palm
civet
human
host
furthermor
presum
asymptomat
infect
sarscovlik
coronavirus
repeatedli
occur
wild
anim
handler
guangdong
provinc
sever
year
sar
epidem
recent
bat
identifi
import
natur
reservoir
viru
therefor
unlik
mass
cull
civet
cat
perform
southern
china
suffici
prevent
spillov
sarscov
sarscovlik
virus
human
popul
search
vaccin
sar
neutral
antibodi
rais
success
experiment
anim
immun
whole
kill
viru
recombin
vaccin
construct
express
sarscov
glycoprotein
spike
correspondingli
studi
immun
respons
sar
patient
shown
appear
neutral
antibodi
coincid
decreas
viru
titer
serum
urin
stool
nasopharyng
secret
addit
benefici
effect
convalesc
plasma
sar
patient
report
neutral
antibodi
sarscov
gener
experiment
vaccin
monoclon
antibodi
mab
technolog
repeatedli
shown
passiv
transfer
experi
protect
mice
infect
reduct
viral
replic
addit
human
mab
gener
phage
display
complet
prevent
lung
patholog
ferret
model
sarscov
infect
abolish
shed
viru
pharyng
secret
shown
block
interact
subunit
protein
cellular
receptor
passiv
immun
use
polyclon
sera
report
curb
outbreak
hepat
viru
prevent
infect
varicellazost
viru
mab
prophylaxi
may
effect
mean
control
sar
outbreak
end
import
mab
product
offer
suffici
breadth
protect
relev
strain
sarscov
prevent
select
neutral
escap
variant
patient
studi
therefor
address
issu
present
characterist
combin
new
sarscov
neutral
human
mab
isol
convalesc
patient
antibodydepend
enhanc
viral
replic
observ
macrophag
one
member
coronaviru
famili
felin
infecti
periton
viru
also
investig
whether
similar
phenomenon
occur
sarscov
infect
primari
human
macrophag
sarscov
report
result
abort
infect
infecti
viru
progeni
produc
therefor
studi
whether
viru
infect
presenc
serial
dilut
serum
convalesc
sar
patient
lead
product
viru
infect
mab
isol
semisynthet
singlechain
variabl
antibodi
fragment
scfv
phage
display
librari
express
human
molecul
purifi
describ
previous
immun
scfv
phage
display
librari
construct
lymphocyt
convalesc
sar
patient
singapor
essenti
describ
librari
scfv
select
bind
uvinactiv
sarscov
essenti
describ
sarscov
frankfurt
strain
prepar
describ
uvirradi
min
uvb
radiat
nm
k
max
nm
scfv
convert
human
format
express
purifi
describ
antirabi
mab
crja
serv
neg
control
research
involv
sarscov
viru
perform
biosafeti
level
contain
sarscov
strain
tcid
ml
mix
equal
volum
serial
dilut
mab
mainten
medium
mm
mem
supplement
vv
fc
incub
h
subsequ
mixtur
inocul
octupl
onto
plate
contain
confluent
cultur
fetal
rhesu
kidney
cell
american
type
cultur
collect
manassa
virginia
unit
state
cell
cultur
observ
develop
cpe
mab
concentr
requir
neutral
calcul
twofold
dilut
seri
accord
spearmankarb
formula
quantit
compar
neutral
potenc
combin
individu
potenc
mab
mix
equimolar
ratio
neutral
potenc
serial
dilut
mix
determin
concept
combin
index
ci
dose
reduct
index
dri
use
quantifi
synergist
effect
describ
previous
serial
dilut
rang
sarscov
strain
incub
presenc
constant
amount
lgml
lgml
h
co
addit
well
contain
cell
virusmab
mixtur
incub
cell
h
co
viru
remov
cell
wash
twice
medium
final
cell
incub
presenc
concentr
mab
ml
medium
supernat
cell
incub
highest
viru
dilut
show
cpe
contain
potenti
escap
virus
harvest
store
use
viru
sampl
freezethaw
serial
dilut
prepar
medium
ad
well
contain
cell
dilut
incub
h
co
presenc
mab
well
overlaid
agaros
contain
mab
concentr
incub
co
individu
escap
viru
plaqu
pick
use
pasteur
pipett
freezethaw
escap
virus
amplifi
cell
identifi
possibl
mutat
sarscov
spike
protein
escap
virus
nucleotid
sequenc
sarscov
open
read
frame
orf
determin
viral
rna
escap
virus
wildtyp
sarscov
viru
isol
convert
cdna
standard
rtpcr
subsequ
cdna
use
nucleotid
sequenc
sarscov
orf
order
identifi
mutat
secondli
neutral
index
determin
escap
virus
therefor
escap
viru
wildtyp
sarscov
tcid
incub
h
co
mab
concentr
addit
cell
viru
allow
attach
cell
h
co
inoculum
remov
cell
wash
twice
medium
replenish
medium
contain
mab
incub
co
medium
harvest
tcid
ml
viru
determin
neutral
index
determin
subtract
number
infecti
viru
particl
express
log
tcid
ml
produc
cell
cultur
infect
viru
presenc
mab
number
infecti
viru
particl
log
tcid
ml
produc
cell
cultur
infect
viru
alon
index
lower
consid
evid
escap
gener
plasmid
encod
recombin
spike
fragment
compris
residu
human
sarscov
strain
shanghai
ly
gzc
clone
palm
civet
cat
deriv
strain
well
express
purif
recombin
protein
previous
describ
direct
elisa
use
recombinantli
express
fragment
compris
amino
acid
perform
mab
describ
competit
elisa
perform
follow
antimyccaptur
fragment
frankfurt
strain
incub
nonsatur
amount
biotinyl
igg
presenc
absenc
compet
igg
bound
biotinyl
igg
detect
streptavidinconjugatedhrp
bd
pharmingen
san
diego
california
unit
state
altern
captur
detect
use
biotinyl
develop
describ
surfac
plasmon
reson
analys
perform
biacor
ab
uppsala
sweden
sensorchip
run
buffer
hbsep
biacor
ab
recombin
immobil
chip
use
amin
coupl
procedur
result
respons
level
approxim
reson
unit
kinet
analysi
perform
determin
associ
rate
constant
k
dissoci
rate
constant
k
affin
k
mab
therefor
concentr
seri
nm
igg
prepar
use
twofold
dilut
hbsep
sampl
inject
duplic
flow
rate
llmin
inject
time
min
dissoci
time
min
sensor
chip
surfac
regener
puls
mm
naoh
biacor
evalu
softwar
biaevalu
version
use
fit
associ
dissoci
curv
concentr
inject
prepar
primari
human
monocytesmacrophag
infect
sarscov
perform
previous
describ
investig
effect
subneutr
dose
antisar
ab
viral
infect
macrophag
serial
dilut
mab
mm
medium
convalesc
serum
sarscov
expos
individu
serum
healthi
individu
mix
sarscov
mm
medium
mix
sarscov
serv
viru
control
virusmab
mixtur
virusserum
mixtur
incub
h
mixtur
ad
duplic
well
contain
macrophag
h
viru
adsorpt
viru
inoculum
remov
infect
cell
wash
macrophag
sfm
cultur
medium
incub
macrophag
sfm
medium
supplement
lgml
penicillin
lgml
streptomycin
sampl
cultur
supernat
collect
day
postinfect
store
viru
titrat
experi
sarscov
titrat
tcid
determin
essenti
describ
rna
isol
infect
macrophag
hour
postinfect
use
rneasi
mini
kit
qiagen
valencia
california
unit
state
accord
manufactur
instruct
quantif
positiveand
negativestrand
viral
rna
perform
realtim
quantit
rtpcr
target
gene
describ
previous
sarscov
rna
level
normal
level
bactin
mrna
full
neutral
curv
wildtyp
sarscov
one
escap
viru
shown
figur
five
neutral
escap
variant
complet
refractori
neutral
sequenc
complet
spike
gene
variant
isol
two
separ
viral
cultur
n
reveal
carri
singl
point
mutat
amino
acid
posit
prolin
leucin
abolish
bind
recombinantli
express
receptorbind
domain
rbd
fragment
display
mutat
figur
mutat
date
observ
neither
sarscov
isol
human
patient
sarscovlik
coronavirus
found
civet
cat
two
independ
experi
repeat
passag
sarscov
presenc
lgml
result
gener
neutral
escap
variant
unpublish
data
antibodi
phage
display
librari
construct
rna
isol
lymphocyt
convalesc
sar
patient
origin
singapor
antibodi
isol
complet
neutral
sarscov
strain
escap
variant
concentr
lgml
tabl
shown
elisa
bind
noncompetit
recombinantli
express
rbd
glycoprotein
wildtyp
sarscov
strain
frankfurt
also
mutat
rbd
escap
variant
figur
complet
neutral
lgml
mab
contrast
prevent
bind
recombin
fragment
compos
amino
acid
vero
cell
unpublish
data
sequenc
variabl
region
heavi
light
chain
deposit
genbank
addit
fragment
recogn
also
bind
rbd
sarscovlik
isol
isol
civet
cat
human
sarscov
mutat
asparagin
serin
amino
acid
partial
recogn
respect
figur
evalu
whether
would
neutral
sarscov
addit
synergist
manner
use
classic
method
titrat
neutral
potenc
equimolar
mixtur
antibodi
compar
dose
respons
neutral
assay
perform
individu
antibodi
figur
data
analyz
appli
median
effect
principl
formul
chou
talalay
combin
index
ci
less
indic
synergist
neutral
observ
three
independ
experi
neutral
wildtyp
sarscov
tabl
evid
dri
mixtur
antibodi
reduc
requir
antibodi
dose
especi
consider
dri
interestingli
also
slightli
enhanc
neutral
escap
virus
figur
investig
chang
affin
possibl
mechan
synergi
k
bind
sequenti
simultan
recombin
rbd
investig
individu
k
valu
nm
nm
respect
antibodi
bind
simultan
nm
bind
nm
compar
dose
reduct
indic
respect
neither
simultan
sequenti
bind
mab
result
chang
k
assay
perform
octupl
data
also
shown
figur
b
applic
c
synergi
indic
ci
sarscov
replic
measur
titer
day
macrophag
absenc
presenc
serial
dilut
mab
control
mab
serum
convalesc
patient
unpublish
data
figur
show
detect
sarscov
posit
p
neg
n
strand
rna
replic
intermedi
rtpcr
assay
positivestrand
rna
detect
h
postinfect
indic
uptak
viru
macrophag
presenc
lgml
slight
increas
viru
uptak
macrophag
suggest
increas
copi
number
positivestrand
rna
figur
contrast
negativestrand
rna
indic
viral
replic
detect
much
lower
level
constant
time
differ
viru
incub
control
antibodi
taken
togeth
result
show
without
monoclon
polyclon
antibodi
macrophag
take
sarscov
uptak
lead
product
viru
replic
releas
infecti
viru
result
show
sarscov
neutral
synergist
human
mab
target
receptorbind
domain
viru
combin
two
mab
expand
breadth
protect
control
potenti
immun
escap
variant
reduc
total
antibodi
concentr
requir
neutral
viru
view
proven
efficaci
passiv
prophylaxi
sarscov
infect
anim
model
use
singl
mab
data
provid
rational
develop
cocktail
mab
human
sar
prophylaxi
although
sar
epidem
success
contain
risk
reemerg
remain
natur
anim
reservoir
intermedi
host
civet
cat
live
anim
market
laboratori
associ
infect
reemerg
commun
spread
sar
beij
februari
requir
quarantin
larg
number
contact
social
econom
consequ
measur
consider
avail
prophylact
therapeut
measur
sarscov
would
greatli
assist
control
futur
reemerg
viru
develop
therefor
remain
high
prioriti
respect
vaccin
develop
consider
progress
made
understand
immun
respons
viru
defin
correl
protect
patient
high
viral
load
shed
sarscov
pharyng
secret
elev
mortal
correspondingli
develop
neutral
antibodi
titer
correl
decreas
viru
titer
serum
urin
stool
nasopharyng
secret
progress
also
made
understand
target
neutral
immun
respons
immun
whole
kill
sarscov
recombin
vector
express
glycoprotein
structur
protein
neutral
antibodi
seem
predominantli
direct
domain
subunit
spike
protein
defin
amino
acid
respons
interact
viru
cellular
receptor
map
rbd
use
panel
mous
mab
led
identif
six
distinct
neutral
epitop
conformationdepend
neutral
potenc
mab
correl
directli
abil
block
interact
recombin
assay
howev
sever
neutral
mab
also
identifi
bind
two
distinct
epitop
rbd
without
inhibit
interact
concept
use
polyclon
monoclon
antibodi
neutral
activ
sarscov
passiv
immun
control
develop
sever
diseas
transmiss
human
human
viru
base
sever
observ
use
convalesc
serum
sar
patient
report
associ
possibl
benefit
event
associ
advers
effect
consequ
commerci
product
sar
antiserum
human
donor
initi
china
passiv
transfer
immun
serum
gener
immun
anim
whole
kill
viru
vectorexpress
fulllength
fragment
reduc
viral
replic
mous
model
sarscov
infect
human
mab
gener
phage
display
immort
human
bcell
sarspati
immun
transgen
mice
shown
display
protect
efficaci
mous
model
addit
human
mab
reduc
sarscov
replic
lung
infect
ferret
complet
prevent
develop
lung
lesion
abolish
viral
shed
pharyng
secret
anim
sarscov
spread
respiratori
fecalor
rout
observ
passiv
immun
success
control
outbreak
hepat
viru
protect
varicellazost
respiratori
syncyti
viru
infect
argu
feasibl
emerg
immun
prophylaxi
sar
outbreak
monoclon
antibodi
prophylaxi
sar
must
meet
certain
criteria
effect
breadth
protect
singl
mab
may
suffici
protect
clinic
relev
strain
viru
suggest
genotyp
sarscov
case
new
outbreak
may
requir
select
optim
neutral
mab
comprehens
analysi
variabl
approxim
fulllength
genom
sarscov
isol
obtain
human
patient
civet
cat
reveal
glycoprotein
especi
rbd
strong
posit
select
pressur
transit
animaltoanim
humantohuman
transmiss
differ
receptor
civet
cat
human
highest
variabl
rbd
observ
within
group
sarscovlik
virus
isol
anim
data
yet
avail
concern
receptor
specif
newli
discov
batcov
interestingli
patient
infect
sarscovlik
virus
milder
cours
diseas
transmit
virus
person
presum
insuffici
adapt
civet
cat
viru
rbd
human
requir
product
infect
human
cell
line
rbd
sarscov
isol
next
sar
epidem
therefor
like
similar
isol
rbd
human
sarscov
isol
highli
conserv
align
sequenc
publish
genbank
reveal
eight
differ
sequenc
ident
strain
human
isol
sarscovlik
isol
obtain
patient
show
highest
rbd
diverg
closest
related
civet
cat
strain
human
mab
bind
well
recombinantli
express
rbd
repres
seven
rbd
variant
includ
less
variant
mutat
found
human
isol
rbd
deriv
civet
cat
sarscovlik
isol
antibodi
deriv
phage
display
convalesc
sar
patient
bind
well
latter
two
variant
addit
other
combin
may
therefor
offer
suffici
protect
sarscov
strain
also
sarscovlik
virus
origin
civet
cat
viral
replic
presenc
mab
especi
subneutr
concentr
carri
risk
select
neutral
escap
variant
therefor
analyz
escap
variant
sarscov
strain
gener
select
pressur
unsuccess
latter
escap
variant
singl
amino
acid
exchang
rbd
report
sarscov
sarscovlik
viru
date
variant
success
neutral
extend
breadth
protect
antibodi
combin
natur
occur
variant
also
possibl
immun
escap
similar
strategi
previous
pursu
develop
mab
product
postexposur
prophylaxi
rabi
neutral
escap
vitro
may
accur
reflect
vivo
situat
combin
need
test
subneutr
concentr
anim
model
sarscov
infect
investig
combin
reveal
antibodi
neutral
wildtyp
sarscov
synergist
vitro
dri
four
two
mab
respect
synerg
neutral
mab
yet
report
sarscov
observ
combin
two
three
four
mab
direct
differ
epitop
envelop
glycoprotein
lead
twoto
tenfold
increas
neutral
titer
mechanist
cooper
bind
mab
may
induc
conform
chang
antigen
therebi
alter
affin
alloster
effect
lead
intermolecular
interact
bival
antibodi
result
interact
fc
region
antibodi
brought
close
contact
determin
elisa
bind
simultan
rbd
subunit
glycoprotein
sarscov
howev
measur
separ
sequenti
simultan
bind
mab
biacor
reveal
enhanc
affin
antibodi
mixtur
individu
affin
especi
anoth
possibl
explan
synerg
could
increas
breadth
protect
differ
quasispeci
viral
isol
heterogen
sequenc
detect
direct
sequenc
sarscov
rna
recov
singl
patient
sampl
adapt
mutat
induc
repeat
cell
cultur
passag
report
therefor
formal
investig
whether
sarscov
quasispeci
format
cell
cultur
may
influenc
outcom
viru
neutral
assay
lastli
could
interfer
bind
subunit
known
unknown
coreceptor
viru
mechan
two
mab
neutral
sarscov
synergist
therefor
remain
present
elus
previous
shown
protect
ferret
challeng
sarscov
dose
mgkg
complet
prevent
lung
patholog
abolish
shed
viru
antibodi
dose
compar
well
requir
dosag
palivizumab
mgkg
protect
atrisk
infant
infect
respiratori
syncyti
viru
current
licens
antivir
monoclon
antibodi
howev
requir
amount
protect
standard
kg
adult
rel
high
would
desir
use
lower
dose
econom
reason
furthermor
even
lower
potenc
preclud
use
standalon
prophylaxi
therefor
observ
fourto
twentyfold
dose
reduct
individu
mab
mixtur
may
hold
attract
option
reduc
total
antibodi
dose
requir
neutral
viru
vivo
time
expand
breadth
protect
studi
also
address
potenti
problem
antibodydepend
enhanc
ade
wellrecogn
phenomenon
observ
infect
anoth
coronaviru
felin
infecti
periton
viru
immun
passiv
transfer
antibodi
shown
mediat
phenomenon
mab
use
map
neutral
enhanc
epitop
spike
glycoprotein
felin
infecti
periton
viru
direct
evid
ade
link
sarscov
infect
human
date
infect
human
macrophag
sarscov
previous
shown
abort
howev
recent
shown
viral
pseudotyp
assay
express
fulllength
spike
glycoprotein
sarscovlik
virus
neutral
either
homolog
heterolog
mous
immun
sera
sera
human
mab
neutral
sarscov
enhanc
infect
pseudotyp
human
adenocarcinoma
cell
use
indic
system
given
ade
felin
infecti
periton
viru
infect
mediat
increas
macrophag
uptak
viru
presenc
neutral
antibodi
perform
human
macrophag
infect
assay
presenc
human
convalesc
serum
type
assay
ade
dengu
ross
river
viru
infect
previous
demonstr
addit
vari
concentr
convalesc
sar
serum
sar
cov
convert
abort
infect
product
one
reduc
likelihood
ade
observ
vivo
passiv
immun
conclus
propos
combin
neutral
mab
target
rbd
sarscov
potenti
control
sarscov
infect
high
level
efficaci
safeti
possibl
reduc
econom
cost
isol
suspect
sar
case
quarantin
expos
contact
prove
effect
control
epidem
howev
direct
indirect
cost
involv
quarantin
measur
substanti
monoclon
antibodi
prophylaxi
ring
vaccin
case
sar
outbreak
may
prove
cost
effect
altern
languag
abstract
chines
translat
abstract
found
doi
kb
doc
genbank
http
wwwncbinlmnihgov
access
number
sarscov
strain
sequenc
variabl
region
heavi
light
chain
deposit
genbank
access
number
respect
studi
done
first
epidem
sar
caus
anim
viru
becam
adapt
spread
peopl
reason
process
wo
nt
repeat
stringent
quarantin
measur
could
prevent
global
epidem
consider
econom
cost
need
way
prevent
sar
develop
healthi
peopl
expos
sarscov
treat
sick
peopl
less
infecti
fight
viru
studi
research
investig
passiv
immun
way
limit
sar
epidem
passiv
immun
shortterm
protect
ill
achiev
inject
antibodiesprotein
recogn
specif
molecul
call
antigen
foreign
organ
bacteria
virus
prevent
organ
caus
diseas
antibodi
passiv
immun
isol
blood
taken
peopl
sar
manufactur
socal
human
monoclon
antibodi
laboratori
one
human
monoclon
previous
made
shown
prevent
lung
damag
ferret
infect
sarscov
stop
infect
anim
infect
other
effect
diseas
prevent
peopl
singl
monoclon
antibodi
might
enough
strain
sarscov
recogn
therefor
act
also
viru
alter
antigen
recogn
grown
low
antibodi
concentr
produc
socal
escap
variant
happen
longer
prevent
escap
variant
kill
human
cell
research
find
research
test
well
combin
two
monoclon
antibodi
control
sarscov
kill
human
cell
first
show
escap
variant
small
chang
part
viru
surfac
interact
human
cell
block
interact
parent
sarscov
strain
escap
variant
made
new
monoclon
prevent
parent
sarscov
stain
escap
virus
kill
human
cell
two
antibodi
bound
neighbor
part
viru
surfac
could
bind
time
also
bound
surfac
sarscov
strain
bind
tri
research
could
gener
viral
escap
variant
unabl
bind
final
effect
two
antibodi
togeth
inhibit
sarscov
kill
human
cell
sum
individu
effect
find
mean
combin
two
human
monoclon
antibodi
recogn
differ
part
sarscov
surfac
interact
human
cell
might
good
way
immun
peopl
passiv
sarscov
might
minim
possibl
escap
variant
aris
broaden
rang
viru
strain
protect
provid
reduc
amount
antibodi
need
effect
protect
approach
tri
peopl
test
animalsresult
experi
done
human
cell
dish
alway
replic
whole
anim
peopl
approach
pass
test
hope
passiv
immun
peopl
sar
close
contact
might
reduc
diseas
sever
infect
peopl
reduc
viral
spread
effect
dramat
quarantin
measur
addit
inform
pleas
access
websit
via
onlin
version
summari
http
medlin
plu
page
sar
us
center
diseas
control
prevent
inform
sar
us
nation
institut
allergi
infecti
diseas
factsheet
research
sar
wikipedia
page
sar
monoclon
antibodi
note
wikipedia
free
onlin
encyclopedia
anyon
edit
